Biomerica, Inc. Stock News

IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global leader in advanced medical diagnostic solutions, is proud to announce that its food intolerance products for Crohn's Disease and Ulcerative Colitis have achieved CE-marking under the European Union's new In Vitro Diagnostic Medical Devices Regulation (IVDR – 2017/746).

IRVINE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global leader in advanced medical diagnostic solutions, is proud to announce that patients with Irritable Bowel Syndrome (IBS) may experience significant relief from abdominal pain when following a dietary therapy created and guided by the inFoods® IBS blood test. The findings from a clinical trial published in ...

- 10-Minute PSA Test for Early Detection of Prostate Specific Antigen (PSA), an Early Warning Sign of Prostate Cancer

- Total Revenue Increases 5% Year-Over-Year - Achieves Sustained Revenue Growth, Improved Gross Margins, and Significant Cost Savings IRVINE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2025 ended November 30, 2...

IRVINE, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical technology company, announces they have recently received three patent notices of allowance covering technology and methods for treating Gastroesophageal Reflux Disease (“GERD”), Crohn's Disease, and Ulcerative Colitis using its proprietary inFoods® Technology. These patents apply to countries ...

IRVINE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, announced that it has been granted an additional 180-day compliance period from the Nasdaq Stock Market LLC ("Nasdaq") to meet the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq Capital Market. This extension allows Biome...

IRVINE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, is excited to announce a major enhancement to its inFoods® IBS platform. US consumers can now seamlessly order the inFoods® IBS test directly from infoodsibs.com and consequently collect a sample in the comfort of their home. As part of this ordering proce...

IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the first quarter of fiscal 2025 ended August 31, 2024.